[go: up one dir, main page]

ES2095926T5 - CYCLOSPORINS - Google Patents

CYCLOSPORINS

Info

Publication number
ES2095926T5
ES2095926T5 ES91810841T ES91810841T ES2095926T5 ES 2095926 T5 ES2095926 T5 ES 2095926T5 ES 91810841 T ES91810841 T ES 91810841T ES 91810841 T ES91810841 T ES 91810841T ES 2095926 T5 ES2095926 T5 ES 2095926T5
Authority
ES
Spain
Prior art keywords
cyclosporins
noveled
noinmunosupresivas
cyclophylines
union
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91810841T
Other languages
Spanish (es)
Other versions
ES2095926T3 (en
Inventor
Soo Young Ko
Hans Kobel
Brigitte Rosenwirth
Dieter Seebach
Rene P Traber
Roland Wenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27517009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2095926(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909023859A external-priority patent/GB9023859D0/en
Priority claimed from GB909023971A external-priority patent/GB9023971D0/en
Priority claimed from GB909023972A external-priority patent/GB9023972D0/en
Priority claimed from GB909023970A external-priority patent/GB9023970D0/en
Priority claimed from GB919116836A external-priority patent/GB9116836D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2095926T3 publication Critical patent/ES2095926T3/en
Publication of ES2095926T5 publication Critical patent/ES2095926T5/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE HA VISTO QUE CICLOSPORINAS DE UNION A CICLOPHILINAS, NOINMUNOSUPRESIVAS SON UTILES EN EL TRATAMIENTO Y PREVENCION DEL AIDS Y DESORDENES RELACIONADOS. TALES CICLOSPORINAS INCLUYEN DERIVADOS DE CICLOSPORINAS NOVEDOSOS MODIFICADOS EN LAS POSICIONES 4 Y/O 5.IT HAS BEEN SEEN THAT CYCLOSPORINS OF UNION TO CYCLOPHYLINES, NOINMUNOSUPRESIVAS ARE USEFUL IN THE TREATMENT AND PREVENTION OF AIDS AND RELATED DISORDERS. SUCH CYCLOSPORINES INCLUDE DERIVATIVES OF NEW NOVELED CYCLOSPORINS MODIFIED IN POSITIONS 4 AND / OR 5.

ES91810841T 1990-11-02 1991-10-30 CYCLOSPORINS Expired - Lifetime ES2095926T5 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909023859A GB9023859D0 (en) 1990-11-02 1990-11-02 Chemical products
GB909023971A GB9023971D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB909023972A GB9023972D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB909023970A GB9023970D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB919116836A GB9116836D0 (en) 1991-08-05 1991-08-05 Organic compounds

Publications (2)

Publication Number Publication Date
ES2095926T3 ES2095926T3 (en) 1997-03-01
ES2095926T5 true ES2095926T5 (en) 2001-02-16

Family

ID=27517009

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91810841T Expired - Lifetime ES2095926T5 (en) 1990-11-02 1991-10-30 CYCLOSPORINS

Country Status (25)

Country Link
US (3) US5767069A (en)
EP (1) EP0484281B2 (en)
JP (1) JP2740775B2 (en)
KR (1) KR100203556B1 (en)
AT (1) ATE148469T1 (en)
AU (1) AU649277B2 (en)
CA (1) CA2054590C (en)
CY (1) CY2159B1 (en)
CZ (1) CZ280909B6 (en)
DE (1) DE69124459T3 (en)
DK (1) DK0484281T4 (en)
ES (1) ES2095926T5 (en)
FI (1) FI111730B (en)
GR (2) GR3022592T3 (en)
HK (1) HK1005741A1 (en)
HU (1) HU212674B (en)
IE (1) IE913824A1 (en)
IL (1) IL99912A (en)
MX (1) MX9101869A (en)
MY (1) MY134806A (en)
NZ (1) NZ240421A (en)
PL (1) PL168609B1 (en)
PT (1) PT99410B (en)
SA (1) SA92120344B1 (en)
SK (1) SK278808B6 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128790A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas Use of a compound for the manufacture of a medicament for the treatment of hiv infection
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
ES2065273B1 (en) * 1993-05-25 1995-09-16 Biogal Gyogyszergyar PROCEDURE FOR THE PURIFICATION OF CYCLOSPORINE A.
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) * 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US6696413B2 (en) 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
ATE209216T1 (en) * 1995-07-17 2001-12-15 Chem Ag C CYCLOSPORINE DERIVATIVES WITH ANTI-HIV EFFECT
JP3089350B2 (en) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド Inhibitors of cyclophilin rotamase activity
WO1997033604A1 (en) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
CN1130373C (en) * 1996-09-13 2003-12-10 诺瓦蒂斯有限公司 Production process
FR2757521B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2757520B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2757522B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2762843B1 (en) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP4261049B2 (en) 1997-10-08 2009-04-30 アイソテクニカ インコーポレイテッド Deuterated cyclosporine analogs and their use as immunomodulators
ZA99981B (en) * 1998-02-17 2000-08-08 Du Pont Pharm Co Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors.
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
FR2780061B1 (en) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
ES2255275T3 (en) 1998-07-01 2006-06-16 Debiopharm S.A. NEW CYCLOSPORINE WITH IMPROVED ACTIVITY PROFILE.
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
ES2256450T3 (en) * 2001-04-20 2006-07-16 Debiopharm S.A. MODIFIED CYCLOSPORIN USED AS A PROFARMACO AND ITS USE.
KR100695611B1 (en) * 2001-05-17 2007-03-14 주식회사 엘지생활건강 [Gamma Hydroxy-En-methyl-L-Leucine 4] Hair Growth Accelerator Using Cyclosporin Derivative as an Active Ingredient
DE60233150D1 (en) * 2001-10-19 2009-09-10 Isotechnika Inc NEW CYCLOSPORIN ANALOG MICROEMULSION PRECONCENTRATES
CN100334106C (en) * 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 Synthesis of cyclosporin analogs
EP1439853A2 (en) * 2001-10-25 2004-07-28 Hans Will Means for inhibition of lentiviruses
US7108988B2 (en) * 2001-11-02 2006-09-19 The J. David Gladstone Institutes Methods of identifying agents for inhibiting lentivirus replication
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2007532507A (en) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト Use of cyclosporine for the treatment of cerebral ischemia and brain and spinal cord injury
BRPI0513317A (en) * 2004-07-13 2008-05-06 Novartis Ag cyclosporins to treat alzheimer's disease
BRPI0513370A (en) 2004-07-14 2008-05-06 Novartis Ag use of a combination of pegylated cyclosporine and interferon for treatment of hepatitis c (hcv)
KR100597309B1 (en) 2004-09-17 2006-07-05 주식회사 핸슨바이오텍 Method for preparing [gamma hydroxylmethyl leucine 4] cyclosporin A using Severkia Benihana
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008514701A (en) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Cyclosporine alkyne analogs and their pharmaceutical use
EP1802650B1 (en) * 2004-10-01 2011-10-26 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
KR100777488B1 (en) 2004-12-15 2007-11-28 주식회사 핸슨바이오텍 Effective and Selective Recovery of Gamma-Hydroxymethylleucine 4 Cyclosporin A from Sebekia benihana Cultures
JP2008525458A (en) * 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト Flaviviridae treatment compounds
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2007141395A1 (en) * 2006-06-02 2007-12-13 Claude Annie Perrichon Management of active electrons
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
NZ584356A (en) * 2007-09-26 2011-10-28 Univ Oregon Health & Science Cyclic undecapeptides and derivatives as multiple sclerosis therapies
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CN102083852A (en) * 2008-06-06 2011-06-01 西尼克斯公司 Cyclosporin analogs and their use in the treatment of HCV infections
NZ590517A (en) * 2008-07-30 2012-12-21 Isotechnika Pharma Inc Nonimmunosuppressive cyclosporine analogue molecules
JP5780969B2 (en) 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド Cyclosporine A derivative
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
GB0909754D0 (en) * 2009-06-05 2009-07-22 Magnani Mauro Drug delivery systems
US8802666B2 (en) * 2009-12-21 2014-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of cyclophilins and uses thereof
KR20120125610A (en) 2009-12-30 2012-11-16 싸이넥시스, 인크. Cyclosporine analogues
CN103153329A (en) 2010-07-16 2013-06-12 美国科技环球有限公司 Use of novel cyclosporine A derivatives in the treatment and prevention of viral infections
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
JP5909495B2 (en) 2010-10-08 2016-04-26 ノバルティス アーゲー Vitamin E formulation of sulfamide NS3 inhibitor
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN107496902B (en) 2010-12-15 2022-01-18 康卓维尔制药公司 Cyclosporin-like molecules modified at amino acid 1 and 3
US20120253007A1 (en) * 2011-03-28 2012-10-04 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Synthesis of Cyclosporin H
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN111449050A (en) 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 Cyclosporine analogues and their uses
KR20220080181A (en) 2019-10-12 2022-06-14 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 Treatment and prevention of nephrotoxin-induced kidney damage
BR112022018929A2 (en) 2020-03-26 2022-12-06 Farsight Medical Tech Shanghai Co Ltd CYCLOPHILIN INHIBITORS AND THEIR USES
US12465629B2 (en) 2020-04-15 2025-11-11 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2455859C2 (en) 1973-12-06 1983-12-15 Sandoz-Patent-GmbH, 7850 Lörrach The antibiotic Cyclosporin A (S 7481 / F-1), its manufacture and use
US4304855A (en) * 1977-05-05 1981-12-08 The Upjohn Company Allylic methyl-hydroxylated novobiocins
CH667274A5 (en) * 1984-03-23 1988-09-30 Sandoz Ag CYCLOSPORINE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
EP0283801A3 (en) * 1987-03-27 1990-05-30 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
DE3888357T2 (en) * 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin derivatives that carry a modified amino acid at position 8.
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4914188A (en) † 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5081024A (en) * 1988-09-05 1992-01-14 Nissan Chemical Industries, Ltd. Process for producing optically active amino acids
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8

Also Published As

Publication number Publication date
US5767069A (en) 1998-06-16
SK278808B6 (en) 1998-03-04
HU212674B (en) 1996-09-30
CS329791A3 (en) 1992-05-13
HU913446D0 (en) 1992-01-28
CY2159B1 (en) 2002-08-23
FI915135L (en) 1992-05-03
MY134806A (en) 2007-12-31
DK0484281T4 (en) 2001-02-05
IL99912A0 (en) 1992-08-18
US5981479A (en) 1999-11-09
DK0484281T3 (en) 1997-02-17
FI915135A0 (en) 1991-10-30
EP0484281A2 (en) 1992-05-06
KR920009390A (en) 1992-06-25
NZ240421A (en) 1993-04-28
HUT62337A (en) 1993-04-28
DE69124459T3 (en) 2001-05-31
EP0484281A3 (en) 1993-02-24
GR3022592T3 (en) 1997-05-31
AU8692391A (en) 1992-05-07
PT99410B (en) 1999-04-30
AU649277B2 (en) 1994-05-19
ATE148469T1 (en) 1997-02-15
DE69124459D1 (en) 1997-03-13
IL99912A (en) 1996-09-12
FI111730B (en) 2003-09-15
PL168609B1 (en) 1996-03-29
US6255100B1 (en) 2001-07-03
MX9101869A (en) 1993-04-01
PL292248A1 (en) 1992-07-27
IE913824A1 (en) 1992-05-22
KR100203556B1 (en) 1999-06-15
JP2740775B2 (en) 1998-04-15
CA2054590A1 (en) 1992-05-03
EP0484281B2 (en) 2000-11-22
ES2095926T3 (en) 1997-03-01
HK1005741A1 (en) 1999-01-22
CZ280909B6 (en) 1996-05-15
EP0484281B1 (en) 1997-01-29
CA2054590C (en) 2003-09-16
JPH05208996A (en) 1993-08-20
SA92120344B1 (en) 2004-01-24
PT99410A (en) 1992-09-30
DE69124459T2 (en) 1997-07-10
GR3035323T3 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ES2095926T5 (en) CYCLOSPORINS
ATE133181T1 (en) DEHYDRODIDEMNINE B
DE69713151D1 (en) CYCLOSPORINE DERIVATIVE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION
HUP9801916A2 (en) Height-adjustable artificial vertebral body
DE10199020I1 (en) Galanthamine or its analogues for the treatment of Alzheimer's disease
AP9100310A0 (en) Tnf inhibitors
ES2056180T3 (en) NEW DERIVATIVES OF 2'-HALOMETILIDEN, 2'-ETENILIDEN AND 2'-ETINIL CITIDINA.
ES2055719T3 (en) DESMANOSIL-TEICOPLANINE DERIVATIVES.
ES2100689T3 (en) SYNERGIZING ASSOCIATION THAT HAS AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS.
ATE81467T1 (en) IMMUNOSUPPRESSION IN IMMUNOTOXIN-BASED TREATMENT OF HUMANS.
ES2066096T3 (en) 4-BENCIL-5-FENIL-2,4-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS AND ITS USE AS ANTICONVULSIVES.
ES2062332T3 (en) ANTI-INFLAMMATORY BENZOXAZOLONES.
GR3001850T3 (en) Expellants of phytopathogenic microbes
ES2066897T3 (en) 5,11-DIHYDRO-6H-PIRIDO (2,3-B) (1,4) BENZODIAZEPIN-6-ONAS AND -TIONAS AND THEIR USE IN THE PREVENTION OR TREATMENT OF AIDS.
SE8802323L (en) 8ALFA-ACYLAMINOERGOLIN, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX9306504A (en) DERIVATIVES OF 3-ARILURACILO AND THE USE OF THE SAME FOR THE CONTROL OF BAD HERBS.
ATE228014T1 (en) COMPOSITIONS AND THEIR USES AGAINST HYPERACUTE TRANSPLANT REJECTION AND CERTAIN DISEASES
ES1007623Y (en) PROTECTOR AGAINST EVAPORATION PRODUCED AT THE BASE OF THE TRUNK OF PLANTS.
MX9709245A (en) Endoparasiticidal agents.
MY128749A (en) Fungicidal mixtures
AU112023S (en) Cloth hanger
MX9800306A (en) Fungicidal mixtures.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 484281

Country of ref document: ES